Shares in Clearside Biomedical (NSDQ:CLSD) have fallen slightly today after the biopharmaceutical company posted fourth quarter 2018 earnings that missed expectations on Wall Street.
The Alpharetta, Ga.-based company reported research and development costs of approximately $17.5 million with a total net loss of $21.6 million, or 68¢ per share, for the three months ended December 31, seeing R&D costs grow 25.5% while losses grew 31.2% when compared with the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business News